Alberto Quaglia, Bernard C. Portmann, Alex S. Knisely, Parthi Srinivasan, Paolo Muiesan, Julia Wendon, Michael A. Heneghan, John G. O'Grady, Marianne Samyn, Dino Hadzic, Anil Dhawan, Giorgina Mieli‐Vergani, Nigel Heaton, Mohamed Rela – 29 September 2008 – Auxiliary liver transplantation (ALT) permits the serial assessment of regeneration in livers of patients with acute liver failure (ALF). Forty‐nine ALF patients [32 adults (median age, 23 years; range, 16‐40 years) and 17 children (median age, 12 years; range, 1‐15 years)] underwent ALT between 1994 and 2004 at King's College Hospital.

Ayşe Caner, Mert Döşkaya, Zeki Karasu, Aysu Değirmenci, Edward Guy, Murat Kılıç, Murat Zeytunlu, Janet Francis, Ata Bozoklar, Yüksel Gürüz – 29 September 2008 – Toxoplasmosis is a serious and potentially life‐threatening disease in liver transplant recipients while they are immunosuppressed. We report the clinical and laboratory findings related to active toxoplasma infection associated with 40 immunosuppressed liver transplant procedures that took place over a 12‐month period at a major transplant unit in Izmir, Turkey.

Dmitriy Nikitin, Linda W. Jennings, Tariq Khan, Edmund Q. Sanchez, Srinath Chinnakotla, Henry B. Randall, Greg J. McKenna, Robert M. Goldstein, Marlon F. Levy, Goran B. Klintmalm – 29 September 2008 – Arterial problems remain a formidable challenge in liver transplantation. In many situations, an aortohepatic conduit can provide a solution. No long‐term results (over 5 years) have been reported.

Rajendra Desai, Neville V. Jamieson, Alexander E. Gimson, Christopher J. Watson, Paul Gibbs, J. Andrew Bradley, Raaj K. Praseedom – 29 September 2008 – Liver transplantation provides a return to a satisfactory quality of life (QOL) for the majority of patients in the short to medium term (first 5 years), but there is very little information on the QOL in the longer term and the factors influencing it. We therefore undertook a single‐center cross‐sectional analysis to determine QOL in patients 10 or more years after liver transplantation.

Gi‐Young Ko, Kyu‐Bo Sung, Hyun‐Ki Yoon, Kyung Rae Kim, Jin Hyoung Kim, Dong Il Gwon, Sung Gyu Lee – 29 September 2008 – Although balloon angioplasty has been accepted as the safe and effective initial treatment to manage hepatic venous outflow abnormalities, it may induce rupture of the fresh anastomosis but also may be ineffective to eliminate various etiologies of venous outflow abnormalities in the early post‐transplant period. Therefore, we performed primary stent placement in 108 patients to treat early‐onset (≤4 weeks) post‐transplant hepatic venous outflow abnormality.

Alexander Kuo, Vivian Tan, Billy Lan, Mandana Khalili, Sandy Feng, John P. Roberts, Norah A. Terrault – 29 September 2008 – The long‐term effects of preemptive antiviral therapy on fibrosis progression in liver transplant recipients with hepatitis C virus (HCV) were examined in a cohort of consecutive liver transplant recipients who received preemptive antiviral therapy for 48 weeks (95% were virologic nonresponders). Control patients were transplanted during this same period but did not receive preemptive therapy.

Philippe Ichai, Didier Samuel – 29 September 2008

David P. Dimmock, J. Kay Dunn, Annette Feigenbaum, Anthony Rupar, Rita Horvath, Peter Freisinger, Bénédicte Mousson de Camaret, Lee‐Jun Wong, Fernando Scaglia – 29 September 2008 – Deoxyguanosine kinase (DGUOK) deficiency is the commonest type of mitochondrial DNA depletion associated with a hepatocerebral phenotype. In this article, we evaluate predictors of survival and therapeutic options in patients with DGUOK deficiency.

Patrick P. McHugh, Hoonbae Jeon, Roberto Gedaly, Thomas D. Johnston, Paul D. DePriest, Dinesh Ranjan – 29 September 2008

Gregory J. Dore, Paul S. Haber – 26 September 2008